Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details) - shares |
Mar. 31, 2022 |
Mar. 31, 2021 |
|---|---|---|
| Anti-dilutive securities | ||
| Warrant issued to purchase common stock | 2,117,094 | 2,117,094 |
| Private Placement | ||
| Anti-dilutive securities | ||
| Warrant issued to purchase common stock | 2,828,125 | 2,828,125 |
| Loan Agreement | ||
| Anti-dilutive securities | ||
| Warrant issued to purchase common stock | 27,548 | 27,548 |
| Second Draw on Loan Agreement | ||
| Anti-dilutive securities | ||
| Warrant issued to purchase common stock | 17,389 | 17,389 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|